Champions and ImClone collaborate on oncology drug review

Champions Biotechnology, a company engaged in the development of advanced preclinical platforms and tumor-specific data to enhance the value of oncology drugs, has established a collaboration with fellow USA-based ImClone Systems for the preclinical evaluation of certain therapeutic antibodies in the latter's clinical development pipeline. As part of the agreement, ImClone will utilize Champions' Biomerk Tumorgrafts in the initial preclinical evaluation.

"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, president of Champions. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates," he added.